More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
Metachronous bladder recurrences after UTUC surgery may require more aggressive or different management than primary NMIBC. Bacillus Calmette Guérin (BCG) may be less effective in patients who develop ...
Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in ...
BCG might be superior to sequential intravesical gemcitabine-docetaxel for reducing the risk of recurrence in patients with high-grade intermediate-risk NMIBC. Given the recent global shortage of ...
In this phase IIb parallel cohort study, patients with BCG-unresponsive carcinoma in situ (CIS) with/without papillary disease received TAR-200 monotherapy (Cohort 2 [C2]), TAR-200 plus cetrelimab (C1 ...
Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of the bladder: Post hoc analysis of two prospective ...
LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...
NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy ...
SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results